13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001512848
Total reported value
$1.6B
$1.6B
32 檔
52.6%
As reported in its official Q2 2025 Form 13F filing, NEA Management Company, LLC's tracked investment portfolio stood at $1.6B with 32 total positions.
In Q2 2025, NEA Management Company, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 18.56% | -19.88% | EXIT | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 16.11% | — | -15.82% | |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 13.84% | — | — | |
| 4 | COUR | Coursera Inc | Stock-Other | 8.49% | +0.31% | — | |
| 5 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 5.81% | +0.78% | — | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 5.44% | +6.56% | +16.29% | |
| 7 | SVRA | Savara Inc | Stock-Other | 4.20% | +1.89% | — | |
| 8 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.15% | -0.16% | +87.59% | |
| 9 | MBX | Mbx Biosciences Inc | Stock-Other | 3.10% | +6.43% | — | |
| 10 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.61% | +4.53% | — | |
| 11 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 2.53% | +0.90% | — | |
| 12 | CELC | Celcuity Inc | Stock-Other | 2.31% | -3.56% | +83.54% | |
| 13 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.99% | +1.96% | +4.58% | |
| 14 | GOSS | Gossamer Bio Inc | Stock-Other | 1.68% | -0.01% | — | |
| 15 | ✓ | Neuehealth Inc | Stock-Other | 1.42% | — | — | |
| 16 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.42% | +0.10% | — | |
| 17 | KRRO | Korro Bio Inc | Stock-Other | 1.03% | +0.24% | — | |
| 18 | CSBR | Champions Oncology Inc | Stock-Other | 0.95% | +0.10% | — | |
| 19 | CVRX | Cvrx Inc | Stock-Other | 0.90% | -0.46% | — | |
| 20 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.83% | -0.02% | — | |
| 21 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.73% | — | — | |
| 22 | ✓ | Senti Biosciences Inc | Stock-Other | 0.60% | +0.09% | — | |
| 23 | OMDA | Omada Health Inc | Stock-Other | 0.50% | — | — | |
| 24 | NKTX | Nkarta Inc | Stock-Other | 0.45% | +0.21% | — | |
| 25 | IVA | Inventiva SA - Adr | Stock-Other | 0.35% | -0.11% | — | |
| 26 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.31% | — | — | |
| 27 | SYBX | Synlogic Inc | Stock-Other | 0.28% | — | — | |
| 28 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.19% | +0.03% | — | |
| 29 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.09% | +0.03% | — | |
| 30 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.07% | +0.19% | -96.67% | |
| 31 | ✓ | Ikena Oncology Inc | Stock-Other | 0.06% | — | — | |
| 32 | 2CH | Wheels Up Experience Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +3% | -15.82% | Trim |
| 2 | ORIC | Oric Pharmaceuticals Inc | +2.2% | +87.59% | Add |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | +2% | — | Unchanged |
| 4 | COUR | Coursera Inc | +1.9% | — | Unchanged |
| 5 | CRSP | CRISPR Therapeutics AG | +1.7% | — | Unchanged |
| 6 | CELC | Celcuity Inc | +1.3% | +83.54% | Add |
| 7 | MBX | Mbx Biosciences Inc | +1.1% | — | Unchanged |
| 8 | ✓ | Inozyme Pharma Inc | +0.6% | — | Unchanged |
| 9 | OMDA | Omada Health Inc | +0.5% | NEW | New buy |
| 10 | PHAT | Phathom Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 11 | ZBIO | Zenas Biopharma Inc | +0.4% | +4.58% | Add |
| 12 | BDTX | Black Diamond Therapeutics I | +0.3% | — | Unchanged |
| 13 | GOSS | Gossamer Bio Inc | +0.2% | — | Unchanged |
| 14 | AUPH | Aurinia Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 15 | ADAPY | Adaptimmune Therapeutics-adr | +0.1% | — | Unchanged |
| 16 | MRKR | Marker Therapeutics Inc | 0% | — | Unchanged |
| 17 | IVA | Inventiva SA - Adr | 0% | — | Unchanged |
| 18 | ✓ | Neuehealth Inc | — | — | Unchanged |
| 19 | SYBX | Synlogic Inc | — | — | Unchanged |
| 20 | ✓ | Ikena Oncology Inc | — | — | Unchanged |
| 21 | 2CH | Wheels Up Experience Inc | — | — | Unchanged |
| 22 | TUYA | Tuya Inc | — | — | Unchanged |
| 23 | ✓ | Affimed N V | 0% | EXIT | Sold out |
| 24 | NKTX | Nkarta Inc | -0.1% | — | Unchanged |
| 25 | OKUR | Onkure Therapeutics Inc-a | -0.1% | — | Unchanged |
| 26 | TRVI | Trevi Therapeutics Inc | -0.1% | +16.29% | Add |
| 27 | ALLKGUSD | Allakos Inc | -0.1% | EXIT | Sold out |
| 28 | GLUE | Monte Rosa Therapeutics Inc | -0.1% | — | Unchanged |
| 29 | ASNSUSD | X4 Pharmaceuticals Inc | -0.2% | -96.67% | Trim |
| 30 | CSBR | Champions Oncology Inc | -0.2% | — | Unchanged |
| 31 | ACLXGBX | Arcellx Inc | -0.4% | — | Unchanged |
| 32 | ✓ | Senti Biosciences Inc | -0.4% | — | Unchanged |
| 33 | BZFD | Buzzfeed Inc | -0.4% | EXIT | Sold out |
| 34 | KRRO | Korro Bio Inc | -0.4% | — | Unchanged |
| 35 | DM* | Desktop Metal Inc-a | -0.5% | EXIT | Sold out |
| 36 | RGLS | Regulus Therapeutics Inc | -0.9% | EXIT | Sold out |
| 37 | CVRX | Cvrx Inc | -1% | — | Unchanged |
| 38 | SVRA | Savara Inc | -1% | — | Unchanged |
| 39 | TEM | Tempus Ai Inc-cl A | -9.7% | EXIT | Sold out |
According to official SEC Form 13F filings, NEA Management Company, LLC reported a total U.S. public equity portfolio value of $1.6B across 32 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, VRNA, RYTM) accounted for 52.6% of total reported equity market value during Q2 2025.
Top New Position Initiated
OMDA
市值: $6.7M
Top Position Liquidated / Trimmed
TEM
前期市值: $126.2M
During Q2 2025, NEA Management Company, LLC's top holdings by market value included ACLXGBX (18.6%)、VRNA (16.1%)、RYTM (13.8%). The largest single position, ACLXGBX, represented 18.6% of total portfolio value.
In Q2 2025, NEA Management Company, LLC made 13 total portfolio adjustments, initiating 1 new buys, adding to 4 positions, trimming 2 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.